Lee et al. (2020) evaluated an entrectinib first-line treatment for ROS1-positive NSCLC; however, in addition to its clinical benefits and prolonged response duration, resistance may be acquired and elicit the need for a subsequent newer generation kinase inhibitor such as third-generation TKI lorlatinib [4,8,31,33]. Here, ROS1 is linked to non-small cell lung carcinoma.